Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians’ experiences and attitudes
- 1 February 2002
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (3) , 397-405
- https://doi.org/10.1097/00002030-200202150-00011
Abstract
To evaluate the impact of official recommendations for non-occupational HIV post-exposure prophylaxis (PEP), issued in France in 1998, on physicians’ prescriptions and attitudes and the occurrence of severe PEP side-effects. Two surveys were carried out among hospital physicians involved in HIV care, before (1997) and after (1999) the publication of recommendations. Questionnaires explored, for the last 12 months, description of PEP requests and prescriptions, detailed description of the latest treated exposure, prescription attitudes towards five exposure scenarios and types of severe side-effects of antiretroviral drugs (in 1999 only). Nationally, from 1997 to 1999, PEP requests and prescriptions increased sevenfold and ninefold, respectively. Most requests followed sexual exposure (71% in 1997 and 86% in 1999;P = 10−6). The proportion of prescriptions for exposure to a known HIV-infected person decreased from 78% in 1997 to 41% in 1999 (P = 10−6). Three-drug combination therapies increased from 46% in 1997 to 83% in 1999 (P = 10−6). In 1999, 13 (0.9%; 95% confidence interval, 0.5–1.5%) severe reversible adverse events occurred among patients on a three-drug regimen. Prescription attitudes based mainly on risk assessment in 1997 (64% versus 33% in 1999) were based mainly on the request of the patient in 1999 (41% versus 11% in 1997). Recommendations were followed by an increase of PEP, particularly after less risky exposures, and a substantial risk of severe side-effects. PEP should be restricted to well-documented exposures for which the risk of transmission outweighs the risk of severe side-effects. Drug regimens should be revised.Keywords
This publication has 12 references indexed in Scilit:
- Unsafe injecting practices among attendees of syringe exchange programmes in FranceAddiction, 2001
- Feasibility of Postexposure Prophylaxis (PEP) against Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: The San Francisco PEP StudyThe Journal of Infectious Diseases, 2001
- Postexposure Prophylaxis After Nonoccupational HIV ExposurePublished by American Medical Association (AMA) ,1998
- Heterosexual Transmission of Human Immunodeficiency Virus: Variability of Infectivity throughout the Course of InfectionAmerican Journal of Epidemiology, 1998
- A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous ExposureNew England Journal of Medicine, 1997
- Toxicity of antiretroviral agentsThe American Journal of Medicine, 1997
- Postexposure Treatment of People Exposed to the Human Immunodeficiency Virus through Sexual Contact or Injection-Drug UseNew England Journal of Medicine, 1997
- Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005AIDS, 1997
- Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenineScience, 1995
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994